A Multicenter, Open-label, Single Arm Study to Evaluate the Immunological Efficacy and Safety of GC3110A. Administered Intramuscularly in Healthy Subjects Aged 65 Years and Older
Phase of Trial: Phase III
Latest Information Update: 02 Jun 2017
At a glance
- Drugs GC 3110A (Primary)
- Indications Influenza virus infections
- Focus Pharmacodynamics
- Sponsors Green Cross
- 24 May 2017 Status changed from active, no longer recruiting to completed.
- 23 Nov 2016 Status changed from recruiting to active, no longer recruiting.
- 17 Oct 2016 Status changed from not yet recruiting to recruiting.